A significant proportion of Medicare beneficiaries may qualify for the weight loss medication semaglutide, dependent on cardiovascular health criteria. Costs could range from $10 billion to $145 billion annually, based on how broadly cardiovascular disease is defined, highlighting a critical decision point for Medicare Part D coverage. A brief research report found that 61% of [...]from SciTechDaily https://ift.tt/Jj3tadp
